Cattral M S, Lilly L B, Levy G A
Department of Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Semin Liver Dis. 2000;20(4):523-31. doi: 10.1055/s-2000-13160.
Prevention of graft rejection while minimizing morbidity remains the single most important objective in liver transplantation. Advances in immunosuppression have provided excellent patient and graft survival with relatively low incidences of acute rejection. However, it is apparent that the toxicity of the present immunosuppressive drugs accounts for much of the morbidity after transplantation. Attention is now being focused on combination drug therapies to reduce morbidity while maintaining the excellent results achieved with present immunosuppressive agents.
在将发病率降至最低的同时预防移植物排斥反应，仍然是肝移植中唯一最重要的目标。免疫抑制方面的进展使患者和移植物存活率显著提高，急性排斥反应的发生率相对较低。然而，目前免疫抑制药物的毒性在很大程度上导致了移植后的发病率。现在人们的注意力集中在联合药物治疗上，以降低发病率，同时维持目前免疫抑制剂所取得的良好效果。
